Cargando…
Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study
BACKGROUND: Most women with ovarian cancer (OC) are diagnosed with advanced disease. They often experience recurrence after primary treatment, and their subsequent prognosis is poor. Our goal was to evaluate the association between use of nonsteroidal antiinflammatory drugs (NSAIDs), including regul...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165482/ https://www.ncbi.nlm.nih.gov/pubmed/36744914 http://dx.doi.org/10.1093/jnci/djac239 |
_version_ | 1785038275300294656 |
---|---|
author | Majidi, Azam Na, Renhua Jordan, Susan J DeFazio, Anna Obermair, Andreas Friedlander, Michael Grant, Peter Webb, Penelope M |
author_facet | Majidi, Azam Na, Renhua Jordan, Susan J DeFazio, Anna Obermair, Andreas Friedlander, Michael Grant, Peter Webb, Penelope M |
author_sort | Majidi, Azam |
collection | PubMed |
description | BACKGROUND: Most women with ovarian cancer (OC) are diagnosed with advanced disease. They often experience recurrence after primary treatment, and their subsequent prognosis is poor. Our goal was to evaluate the association between use of nonsteroidal antiinflammatory drugs (NSAIDs), including regular and low-dose aspirin, and 5-year cancer-specific survival after an OC diagnosis. METHODS: The Ovarian cancer Prognosis And Lifestyle study is a prospective population-based cohort of 958 Australian women with OC. Information was gathered through self-completed questionnaires. We classified NSAID use during the year prediagnosis and postdiagnosis as none or occasional (<1 d/wk), infrequent (1-3 d/wk), and frequent (≥4 d/wk) use. We measured survival from the start of primary treatment: surgery or neoadjuvant chemotherapy for analyses of prediagnosis use, or 12 months after starting treatment (postdiagnosis use) until the earliest of date of death from OC (other deaths were censored) or last follow-up to 5 years. We used Cox proportional hazards regression to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) and applied inverse-probability of treatment weighting to minimize confounding. We also calculated restricted mean survival times. RESULTS: Compared with nonusers and infrequent users, we observed better survival associated with frequent NSAID use prediagnosis (HR = 0.73, 95% CI = 0.55 to 0.97) or postdiagnosis (HR = 0.65, 95% CI = 0.45 to 0.94). Estimates were similar for aspirin and nonaspirin NSAIDs, new and continuous users and in weighted models. These differences would translate to a 2.5-month increase in mean survival by 5 years postdiagnosis. There was no association with acetaminophen. CONCLUSIONS: Our findings confirm a previous study suggesting NSAID use might improve OC survival. |
format | Online Article Text |
id | pubmed-10165482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-101654822023-05-09 Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study Majidi, Azam Na, Renhua Jordan, Susan J DeFazio, Anna Obermair, Andreas Friedlander, Michael Grant, Peter Webb, Penelope M J Natl Cancer Inst Article BACKGROUND: Most women with ovarian cancer (OC) are diagnosed with advanced disease. They often experience recurrence after primary treatment, and their subsequent prognosis is poor. Our goal was to evaluate the association between use of nonsteroidal antiinflammatory drugs (NSAIDs), including regular and low-dose aspirin, and 5-year cancer-specific survival after an OC diagnosis. METHODS: The Ovarian cancer Prognosis And Lifestyle study is a prospective population-based cohort of 958 Australian women with OC. Information was gathered through self-completed questionnaires. We classified NSAID use during the year prediagnosis and postdiagnosis as none or occasional (<1 d/wk), infrequent (1-3 d/wk), and frequent (≥4 d/wk) use. We measured survival from the start of primary treatment: surgery or neoadjuvant chemotherapy for analyses of prediagnosis use, or 12 months after starting treatment (postdiagnosis use) until the earliest of date of death from OC (other deaths were censored) or last follow-up to 5 years. We used Cox proportional hazards regression to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) and applied inverse-probability of treatment weighting to minimize confounding. We also calculated restricted mean survival times. RESULTS: Compared with nonusers and infrequent users, we observed better survival associated with frequent NSAID use prediagnosis (HR = 0.73, 95% CI = 0.55 to 0.97) or postdiagnosis (HR = 0.65, 95% CI = 0.45 to 0.94). Estimates were similar for aspirin and nonaspirin NSAIDs, new and continuous users and in weighted models. These differences would translate to a 2.5-month increase in mean survival by 5 years postdiagnosis. There was no association with acetaminophen. CONCLUSIONS: Our findings confirm a previous study suggesting NSAID use might improve OC survival. Oxford University Press 2023-02-06 /pmc/articles/PMC10165482/ /pubmed/36744914 http://dx.doi.org/10.1093/jnci/djac239 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Article Majidi, Azam Na, Renhua Jordan, Susan J DeFazio, Anna Obermair, Andreas Friedlander, Michael Grant, Peter Webb, Penelope M Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study |
title | Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study |
title_full | Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study |
title_fullStr | Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study |
title_full_unstemmed | Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study |
title_short | Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study |
title_sort | common analgesics and ovarian cancer survival: the ovarian cancer prognosis and lifestyle (opal) study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165482/ https://www.ncbi.nlm.nih.gov/pubmed/36744914 http://dx.doi.org/10.1093/jnci/djac239 |
work_keys_str_mv | AT majidiazam commonanalgesicsandovariancancersurvivaltheovariancancerprognosisandlifestyleopalstudy AT narenhua commonanalgesicsandovariancancersurvivaltheovariancancerprognosisandlifestyleopalstudy AT jordansusanj commonanalgesicsandovariancancersurvivaltheovariancancerprognosisandlifestyleopalstudy AT defazioanna commonanalgesicsandovariancancersurvivaltheovariancancerprognosisandlifestyleopalstudy AT obermairandreas commonanalgesicsandovariancancersurvivaltheovariancancerprognosisandlifestyleopalstudy AT friedlandermichael commonanalgesicsandovariancancersurvivaltheovariancancerprognosisandlifestyleopalstudy AT grantpeter commonanalgesicsandovariancancersurvivaltheovariancancerprognosisandlifestyleopalstudy AT webbpenelopem commonanalgesicsandovariancancersurvivaltheovariancancerprognosisandlifestyleopalstudy |